Safety Study of High-dose Methylprednisolone in Fast-track Total Knee Arthroplasty

Safety Aspects of High-Dose Methylprednisolone in Fast-track Total Knee Arthroplasty

It has been shown that a single high dose of steroid before surgery may reduce pain the first 48 hours after insertion of a new joint in the knee, a so called "total knee arthroplasty" (TKA). Consequently, this has been introduced as standard treatment of most patients at several Danish orthopedic departments. Although there are some concerns about the possibility of increased risk of prosthesis infections, this has not been proved in previous studies. However the studies are few, have limited number of patients and are not done using a standardized perioperative set-up.

This study is made to monitor the safety of a single high dose steroid injection before TKA, with regards to prosthesis infection within one year of surgery.

We hypothesize that there will be no increase in infections in patients receiving steroid injection before TKA compared to a historical cohort of patents who did not receive a steroid injection before their TKA.

Study Overview

• Status: Completed
• Conditions: Infection of Total Knee Joint Prosthesis

Detailed Description

In order to reduce pain intensity as much as possible after surgical procedures, modern multimodal analgesic strategies using different analgetics targeting different mechanism of the pain reception system are used. At the same time this may reduce the use of opioids, which commonly cause sideeffects such as nausea, vomiting, obstipation,urinary retention, itching, respiratory suppression and sedation.

In spite of the use of a wide perioperative multimodal analgesia, pain after total knee arthroplasty (TKA), is stil a considerable clinical problem and need for optimisation of the immediate postoperative pain treatment. There is evidence that "high"dose glucocorticoids administered preoperatively reduces the level of pain and the use of opioids after surgery. A recent review did not give cause for concern regarding use of glucocorticoids in TKA,but found that data on longterm safety aspects are lacking, why no recommendations could be made.

As the limited evidence presently points to af benefit of glucocorticoids without serious side effects, the treatment has been introduced as standard treatment in TKA at several of the departments participating in the Lundbeck Foundation Centre for fast-track Hip and Knee Replacement collaboration.

This study is made to monitor the safety of high dose steroid injection before TKA, with regards to prosthesis infection within one year of surgery.

We hypothesize that there will be no increase in infections in patients receiving steroid injection before TKA compared to a historical cohort of patents who did not receive a steroid injection before their TKA.

• Study Type: Observational
• Enrollment (Anticipated): 6000

Contacts and Locations

Study Locations

• Denmark
  • Gentofte, Denmark
    • Gentofte University Hospital
  • Judland
    • Aarhus, Judland, Denmark, 8000
      • Aarhus University Hospital
    • Farsoe, Judland, Denmark, 9640
      • Farsoe Hospital
    • Grindsted, Judland, Denmark, 7200
      • Sydvestjydsk Sygehus
    • Holstebro, Judland, Denmark, 7500
      • Holstebro Hospital
    • Vejle, Judland, Denmark, 7100
      • Vejle Hospital
    • Viborg, Judland, Denmark, 8800
      • Viborg Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Consecutive unselcted patients with unilateral elective total fast-track knee arthroplasty in a standardized perioperative set-up and with completed prospective registration of preoperative chartacteristics and co-morbidity

Description

Inclusion Criteria:

• Patients scheduled for primary unilateral elective TKA and no contraindications for high-dose Methylprednisolone preoperatively
• Danish Social security number

Exclusion Criteria:

One of the following contraindications for Methylprednisolone:

• Allergy against Methylprednisolone.
• Currently in systemic treatment with glucocorticoid
• Current gastric ulcer
• Insulin dependent diabetes mellitus

Further contraindications are at the discretion of the individual department/surgeon. The cohort without preoperative Methylprednisolone treatment will be followed as a separate cohort to identify potential selection bias.

- Citizens without Danish social security number are not eligible for this study as follow-up is not possible.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
High dose Steroid; Patients scheduled for primary unilateral elective TKA Age >17 years none of the following contraindications for Methylprednisolone: Allergy against Methylprednisolone.; Currently in systemic treatment with glucocorticoid; Current gastric ulcer; Insulin dependent diabetes mellitus Citizens without Danish social security number are not eligible for this study as follow-up is not possible.
Historical cohort; Patients having primary unilateral elective TKA before initiation of Methylprednisolone as standard treatment age >17 years, Danish social security number and none of the following at time of surgery: systemic treatment with glucocorticoid defined as: regular prescriptions on glucocorticoid within 2 months prior to surgery.; gastric ulcer defined as: prescriptions on drugs used in "triple therapy" for Helicobacter Pylori infection or prescriptions on antiacids/proton pump inhibitors beginning 1 month before surgery; Insulin dependent diabetes mellitus defined as: any prescriptions on insulin within 6 months prior to surgery
Procedures without Steroid; Patients scheduled for primary unilateral elective TKA and age >17 years but who did not receive high dose Methylprednisolone regardless of reason.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
prosthesis related infections within 1 year after TKA	Causes if infection are subdivided into the following: Deep prosthesis related infection; Superficial infection (defined as surgery verified infection above level of the fascia); Clinical / paraclinical suspicion of infection only treated with intravenous antibiotics (no surgical procedure); Possible infection, but no clinical/paraclinical suspicion of infection, why the patient is discharged without intravenous antibiotic treatment/surgery.; Surgical wound revision (no clinical/paraclinical suspicion of infection); Surgical knee manipulation due to limited range of movement (no clinical/paraclinical suspicion of infection).; Surgery due to aseptic non-traumatic loosening of the knee.; Surgery due to traumatic loosening of the knee	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency and cause of hospital stay >4 days	Patients admitted for >4 days will have their discharge files reviewed with regards to causes of this prolonged" stay. This in accordance with the method used in the Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement registry trials (Clinicaltrials.gov identifier:NCT01515670)	primary admission
Frequency and causes of 90 days readmissions	These will be found through review of medical files and defined as readmission possibly related to surgery and with overnight stay in hospital. These will be classified according to the method used in the ongoing trials in the Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement registry (Clin.trials ID:NCT01515670)	90 days after surgery
Frequencies and causes of readmissions to orthopedic departments 12 months after TKA.	These will be found through review of medical files and classified appropriately into broad categories depending on data. Detailed information on each case will be recorded	1 year
mortality	Incidence of 90 days and 1 year mortality will be reported	90 days and 1 year

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prosthesis related infections 24 months after TKA	A separate outcome regarding incidence of prosthesis related infections, as defined in the primary outcome, is planned. This will not be part of the initial study, but is planned to be an independent follow-up study	2 years

Collaborators and Investigators

• Sponsor: Rigshospitalet, Denmark
• Collaborators: The Lundbeck Foundation Centre for Fast-track Hip and Knee Arthroplasty
• Investigators: Principal Investigator: Christoffer C Jørgensen, MD, Section for Surgical Pathophysiology Copenhagen University, Rigshospitalet; Principal Investigator: Troels H Lunn, MD, PhD, Section for Surgical Pathophysiology, Copenhagen University, Rigshospitalet; Study Chair: Henrik Kehlet, MD Prof PhD, Secton for Surgical Pathophysiology, Copenhagen University , Rigshospitalet

Publications and helpful links

Helpful Links

• webpage of the Lundbeck Foundation Centre for fast-track Hip and Knee Replacement

Study record dates

Study Major Dates

• Study Start: October 1, 2013
• Primary Completion (ACTUAL): October 1, 2015
• Study Completion (ACTUAL): October 1, 2016

Study Registration Dates

• First Submitted: December 18, 2013
• First Submitted That Met QC Criteria: December 18, 2013
• First Posted (ESTIMATE): December 24, 2013

Study Record Updates

• Last Update Posted (ACTUAL): May 9, 2022
• Last Update Submitted That Met QC Criteria: May 6, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Safety; Total knee arthroplasty; Steroid; Infections; Fast-track; Orthopedic surgery
• Additional Relevant MeSH Terms: Infections
• Other Study ID Numbers: RH-0703